Aspirin resistance: is it real? Is it clinically significant?

[1]  M. Furman,et al.  Resistance to antiplatelet drugs , 2006 .

[2]  Deepak L. Bhatt,et al.  Aspirin and clopidogrel resistance: an emerging clinical entity. , 2006, European heart journal.

[3]  J. Dalen.  Aspirin to prevent heart attack and stroke: what's the right dose? , 2006, The American journal of medicine.

[4]  Colin Baigent,et al.  Low-dose aspirin for the prevention of atherothrombosis. , 2005, The New England journal of medicine.

[5]  P. Gurbel,et al.  Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. , 2005, Journal of the American College of Cardiology.

[6]  A. Maree,et al.  Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. , 2005, Journal of the American College of Cardiology.

[7]  A. Jacobs,et al.  Aspirin resistance and atherothrombotic disease. , 2005, Journal of the American College of Cardiology.

[8]  Hung-Fat Tse,et al.  Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. , 2005, The American journal of medicine.

[9]  S. Steinhubl,et al.  Resistance to antiplatelet resistance is it justified? , 2005, Journal of the American College of Cardiology.

[10]  J. Eikelboom,et al.  Aspirin resistance: position paper of the Working Group on Aspirin Resistance , 2005, Journal of thrombosis and haemostasis : JTH.

[11]  M. Reeves,et al.  Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. , 2005, The American journal of cardiology.

[12]  A. Michelson.  Platelet function testing in cardiovascular diseases. , 2004, Circulation.

[13]  V. Fuster,et al.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[14]  M. Rosen,et al.  Cardiac Memory Evolves With Age in Association With Development of the Transient Outward Current , 2004, Circulation.

[15]  S. Steinhubl,et al.  Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[16]  R. Carroll,et al.  A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. , 2004, The Journal of laboratory and clinical medicine.

[17]  Deepak L. Bhatt.  Aspirin resistance: more than just a laboratory curiosity. , 2004, Journal of the American College of Cardiology.

[18]  C. Lau,et al.  Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. , 2004, Journal of the American College of Cardiology.

[19]  Z. Vered,et al.  Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? , 2004, American heart journal.

[20]  P. Block,et al.  Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. , 2003, The American journal of cardiology.

[21]  E. Topol,et al.  Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease: Reply , 2003 .

[22]  R. Talbert,et al.  Aspirin Dosage and Thromboxane Synthesis in Patients with Vascular Disease , 2003, Pharmacotherapy.

[23]  E. Topol,et al.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. , 2003, Journal of the American College of Cardiology.

[24]  D. Atar,et al.  Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. , 2003, European journal of pharmacology.

[25]  H. Arnesen,et al.  Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. , 2002, Thrombosis research.

[26]  E. Favaloro.  Clinical application of the PFA-100® , 2002, Current opinion in hematology.

[27]  L. Christiaens,et al.  Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. , 2002, Thrombosis research.

[28]  S. Yusuf,et al.  Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events , 2002, Circulation.

[29]  M. Halushka,et al.  Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? , 2002, Circulation.

[30]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[31]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[32]  E. Topol,et al.  Profile and prevalence of aspirin resistance in patients with cardiovascular disease. , 2001, The American journal of cardiology.

[33]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[34]  S. Steinhubl,et al.  Rapid platelet-function assay: an automated and quantitative cartridge-based method. , 1999, Circulation.

[35]  K. Grotemeyer,et al.  Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. , 1993, Thrombosis research.

[36]  H. Topka,et al.  Aspirin non-responder status in patients with recurrent cerebral ischemic attacks , 2003, Journal of Neurology.

[37]  S. Yusuf,et al.  Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. , 2000 .